304 related articles for article (PubMed ID: 3282579)
1. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of anthracyclines.
Robert J; Gianni L
Cancer Surv; 1993; 17():219-52. PubMed ID: 8137342
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
4. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics and metabolism of anthracyclines in man].
Robert J
Pathol Biol (Paris); 1987 Jan; 35(1):27-30. PubMed ID: 3550609
[TBL] [Abstract][Full Text] [Related]
6. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
7. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
Arcamone F
Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
9. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
[TBL] [Abstract][Full Text] [Related]
11. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
12. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Tidefelt U; Prenkert M; Paul C
Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
Tamassia V; Pacciarini MA; Moro E; Piazza E; Vago G; Libretti A
Int J Clin Pharmacol Res; 1987; 7(5):419-26. PubMed ID: 3478310
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
15. New anthracycline analogs in advanced breast cancer.
Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
[TBL] [Abstract][Full Text] [Related]
16. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
17. [Adriamycin and its analogs].
Arcamone F
Tumori; 1984 Apr; 70(2):113-9. PubMed ID: 6587651
[TBL] [Abstract][Full Text] [Related]
18. [Anthracycline transport in sensitive and resistant leukemia cells].
Erttmann R; Erb N; Forcadell de Dios P; Neurath C; Looft G; Landbeck G
Klin Padiatr; 1989; 201(1):40-5. PubMed ID: 2704176
[TBL] [Abstract][Full Text] [Related]
19. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
Dine T; Cazin JC; Gressier B; Luyckx M; Brunet C; Cazin M; Goudaliez F; Mallevais ML; Toraub I
Pharm Weekbl Sci; 1992 Dec; 14(6):365-9. PubMed ID: 1475177
[TBL] [Abstract][Full Text] [Related]
20. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
